Tagged with

Dx assays Nine months ago you were appointed CEO of the company. What brought you to Dx assays? I think Dx Assays is a very interesting opportunity, which is why I came here. It is unusual in that it is not a traditional start-up diagnostics company. We are a company that carries…

ASLAN pharmaceuticals Why did you decide to start your own company? I started my career as a scientist with a real passion for molecular biology, and moved into pharmaceutical R&D working for AstraZeneca. After five or so years I was very keen to get commercial exposure, to see how we actually access…

Takeda Global Research & Development Center (Asia) What is the global R&D vision of Takeda, Japan’s largest pharmaceutical company that recently celebrated its 230th birthday? Takeda’s global R&D vision is committed to the discovery and development of innovative solutions that addresses unmet medical needs of patients. What distinguishes our R&D vision is an emphasis on innovation and…

Boehringer Ingelheim Singapore What is the presence of Boehringer Ingelheim (BI) in Southeast Asia? In 2009, Boehringer Ingelheim decided to establish a regional operating unit for its human pharmaceutical division (prescription and OTC products) in Southeast Asia that would be managed from Singapore. This business unit was designated to oversee of all the…

Alandra Medical México Before we get into the company’s activities and market, could you give us a brief rundown of your past working experience prior to Alandra Medical? My experience outside of the United States is extensive, since I had been work-ing for Intel Corp. for more than twenty years and lived in…

Would you begin by outlining the key milestones & achievements of the NHMRC in the past four years? The first point is the development of our initiatives on an international level: for example, we joined the International Cancer Genome Consortium and we are funding pancreatic cancer and ovarian cancer both…

Lilly has invested over one billion EUR in its Kinsale site to date—including a recent 330 million EUR expansion that positions Ireland as a key location for Lilly’s biotech pipeline. How has this operation developed over time?  Eli Lilly first invested in Ireland in 1980. The company initially developed a…

Sanofi - Belgium Mr Hendrickx, considering that you have been with Sanofi for over a decade, what would you describe as the single most important change in Sanofi’s business model? In essence, it is the diversification of Sanofi into a wide range of business activities. In the past, Sanofi was very successful at…

Menarini Austria Dr. Nikitsch, you started Menarini’s Austrian operations almost 13 years ago. Would you say that Menarini’s presence in Austria today reflects the vision you had for the company in Austria at its creation? I would go beyond this statement and say that Menarini Austria is more today than we expected…

Austroplant Arzneimittel Can you give our readers a snapshot of Austroplant’s scope of activities and its structure in Austria and the central European market? Austroplant/Dr Peithner belongs to the Schwabe Group, the worldwide leader in herbal medicine products. It was sold to the Schwabe Group as a family business in 2009. Dr.…

Merck Austria Dr Prchla, you have been heading Merck’s Austrian subsidiary over the past eighteen months. What do you see as the key strengths of your company today? Mirroring the company’s structure, the Austrian affiliate gathers several divisions under one roof. Merck Serono is the largest division of Merck Austria: it markets…

Biopark Charleroi Brussels South Could you tell our readers who are not familiar with the Biopark with an introduction of the Biopark and its institutes? The BioPark of Charleroi Brussels South is a campus where major biomedical research infrastructures of the Université Libre de Bruxelles (ULB) have been established since 1999. It was a…